Market Minds Advisory
Chromatography Resin Market

Chromatography Resin Market: Purification Capacity Meets Cell And Gene Therapy Complexity

A single batch of monoclonal antibody or viral vector product can require thousands of liters of resin capacity, and manufacturers keep discovering that protein A supply, not fermentation capacity, is often the actual bottleneck.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.6BMarket Size 2025
2036 FORECAST VALUE$8.9BBase Case , 2026 to 2036
CAGR 2026 TO 20368.6 %Bull 9.9% / Bear 7.3%
INCREMENTAL OPPORTUNITY$5.0BNet 10- year value creation
EXPANSION MULTIPLE2.28x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Chromatography resin demand is shifting from single-mode purification toward multimodal and synthetic affinity chemistries, a change large enough that dynamic binding capacity, not raw resin volume alone, increasingly determines which resin families biomanufacturers actually specify for their purification trains nationwide. across major markets.
Multimodal and synthetic affinity resins grow fastest at 13.4%, roughly 1.56 times the overall rate, as biomanufacturers increasingly demand resin chemistries that handle cell and gene therapy purification challenges traditional protein A media cannot address alone. East Asia holds the largest regional share at 28%, reflecting China's rapidly scaling contract development and manufacturing organization capacity across major regional biologics facilities today. Few other regions currently match this combination of manufacturing scale and outsourcing depth.
Competitive intensity stays concentrated: five manufacturers control over two thirds of revenue, led by Cytiva and Merck KGaA through years of accumulated ligand chemistry research and manufacturing scale investment that smaller specialists still struggle to replicate. Rising multimodal adoption keeps expanding demand across nearly every major biomanufacturing network today, forcing manufacturers to carry broader validation data than legacy single-mode products required. Chinese manufacturers are gaining traction in standard deals.
Market Definition
The chromatography resin market covers protein A affinity, ion exchange, size exclusion, mixed-mode, and multimodal resins used in biopharmaceutical downstream purification and separation processes. It excludes analytical chromatography columns and resins used exclusively for small-molecule pharmaceutical purification unrelated to biologics manufacturing.
Base Year Value
$3.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.6% base case. Bull 9.9%. Bear 7.3%.
Fastest Growth Segment
Multimodal and Synthetic Affinity Resin: 13.4% CAGR
Fastest Growth Country
China: 11.6% CAGR
Fastest Growth Region
South Asia and Pacific: 10.6% CAGR
Largest Region
East Asia: 28% of 2025 global value
Market Leaders
Cytiva, Merck KGaA, Bio-Rad Laboratories, Tosoh, Repligen. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Chromatography Resin Market Forecast Scenarios

chromatography-resin-market-size-forecast-scenario-1787306774424
Between 2020 and 2025 the market grew at roughly 7.9% annually, accelerating as monoclonal antibody manufacturing capacity expanded globally and cell and gene therapy purification requirements moved from pilot-scale research into commercial-scale manufacturing across major biologics facilities worldwide. Retailer and payer reimbursement programs expanded steadily across this same period too. Occupational referral patterns shifted meaningfully during this same period.
The base case carries the market to 8.6% annual growth through three commercial mechanisms working together. First, multimodal adoption keeps expanding as biomanufacturers increasingly demand documented process simplification. Second, protein A demand keeps rising alongside expanding biosimilar manufacturing volume. Third, China's CDMO capacity keeps converting rising biologics outsourcing demand into direct resin orders nationwide each year, reinforcing the broader purification technology transition already well underway across the region. That combined momentum keeps pricing power intact across major manufacturing corridors.
The bull case, 9.9%, assumes accelerated multimodal approval activity and faster CDMO capacity expansion pulls forward resin demand more quickly than currently modeled across major biologics markets worldwide, particularly across Asia. The bear case, 7.3%, assumes protein A supply caution and persistent ligand manufacturing constraints keep sequential single-mode purification dominant well beyond the current decade of forecast coverage tracked here.

Where Purification Capacity Meets Cell And Gene Therapy Complexity

Three forces converge on this market simultaneously. Multimodal adoption keeps expanding as biomanufacturers increasingly demand documented process simplification. Protein A demand keeps rising alongside expanding biosimilar manufacturing volume. And China's CDMO capacity keeps converting rising biologics outsourcing demand into direct resin orders nationwide across its manufacturing network.
MARKET CONCENTRATIONCR5: 68%Top five manufacturers control over two thirds of revenue
AVERAGE RESIN COSTUSD 3,500 to 18,000 per literCosts vary sharply between standard and affinity resin chemistries
TOP PRODUCING COUNTRYUnited States: 27% of global unit outputConcentrated specialty polymer manufacturing expertise drives output here
RESIN REUSE CYCLE COUNT50 to 200 cycles per resin batchCycle count varies sharply between standard and affinity chemistries
BASE MATERIAL COST SHARE39% of COGSSpecialty agarose and synthetic polymer sourcing dominate cost structure
SINGLE-USE SYSTEM ADOPTION RATE34% of purification trainsShare of purification systems now using single-use resin formats
Commercially, this market behaves like a specialty biomanufacturing business layered onto a genuinely capacity-constrained purification funnel that remains incomplete across many manufacturing facilities worldwide. Manufacturers compete on binding capacity validation depth and process yield data as much as on price, since biomanufacturers increasingly demand published performance data before specifying a resin into a standard validated purification process. That validation depth increasingly separates leading manufacturers from single-mode-only competitors across nearly every major biomanufacturing market tracked here. Buyers increasingly expect published performance data before committing to a long-term supply relationship.
Over the next decade expect continued transition beyond sequential single-mode purification into multimodal and modality-specific protocols. China's CDMO capacity will keep anchoring regional volume growth across its expanding manufacturing network. And binding capacity documentation, more than raw resin volume alone, will increasingly determine which manufacturers biomanufacturers actually specify into standard purification protocols going forward.

Market Trends

Biomanufacturers Adopt Multimodal Purification Chemistries Fast

Biomanufacturers increasingly adopt multimodal resin chemistries that combine multiple separation mechanisms in a single purification step, a practice that has converted downstream process design from a sequential single-mode workflow into an integrated, fewer-step purification train across major biologics manufacturing facilities. This shift addresses a genuine throughput constraint, since traditional single-mode chromatography sequences require meaningfully more processing steps and buffer volume than multimodal approaches typically demand for comparable purity outcomes. Several manufacturers have expanded multimodal resin portfolios with published yield data, positioning documented process simplification as the category's clearest growth driver heading into the next several years of adoption.
Market Impact: Adds 19% share via capacity growth

Cell And Gene Therapy Manufacturing Demands New Resin Chemistries

Cell and gene therapy manufacturers increasingly demand resin chemistries specifically engineered for viral vector and cell-based product purification, a shift that has converted resin selection from a protein-purification-only decision into a broader modality-specific specification process across major advanced therapy manufacturing facilities. This shift addresses a genuine purification gap, since standard protein A resins designed for monoclonal antibodies cannot effectively purify viral vectors or cell-based therapeutics without meaningful chemistry modification. Several manufacturers have launched viral vector-specific resin platforms with published recovery data, positioning documented modality-specific performance as a durable differentiator across the broader biologics manufacturing industry worldwide.
Market Impact: Anchors 22% of regional resin volum

Market Opportunities and Growth Drivers

Expanding Biologics Manufacturing Capacity Drives Resin Demand

Biopharmaceutical companies worldwide keep expanding monoclonal antibody and biologics manufacturing capacity, converting chromatography resin demand into a durable growth driver independent of any single manufacturer's product launch cycle. This creates demand that spans nearly every major manufacturing market simultaneously, since capacity expansion directly increases the population of purification trains requiring resin regardless of the biologics modality tracked in this review. Manufacturers increasingly design resins for narrower application categories, converting what was once a single uniform resin category into a broader portfolio of application-specific chemistries across the wider biomanufacturing system worldwide.
Market Impact: Leaves 24% of demand unmet

China's CDMO Capacity Anchors Regional Demand

China's continued investment in contract development and manufacturing organization capacity keeps converting rising biologics outsourcing demand directly into resin orders capable of serving both established coastal manufacturing hubs and increasingly inland provincial facilities nationwide each year. Domestic Chinese manufacturers increasingly supply standard ion exchange and size exclusion resins that previously relied on imported specifications, giving the country meaningful production self-sufficiency and expanding distribution capability across its biomanufacturing network. This capacity buildout gives China outsized influence over regional demand growth, since Chinese CDMO investment decisions convert directly into resin orders at meaningful, repeatable scale.
Market Impact: Adds 27% to per-batch process cost

Market Restraints and Challenges

Limited Protein A Manufacturing Capacity Constrains Supply

Protein A ligand manufacturing capacity remains concentrated among a small number of specialized producers, a limitation that keeps addressable resin supply well below the actual demand growth trajectory of expanding biologics manufacturing worldwide. The root cause is manufacturing complexity: protein A ligand production requires specialized fermentation and purification expertise that has not scaled fast enough to match rising downstream demand. The impact falls hardest on smaller biomanufacturers without long-term supply agreements, since they face allocation constraints during industry-wide capacity shortages. Some manufacturers are responding by qualifying synthetic affinity ligand alternatives that reduce protein A dependency directly.
Market Impact: Cuts purification process steps by

High Resin Cost Limits Smaller Manufacturer Adoption

Affinity and multimodal resins cost considerably more than standard ion exchange media, a limitation that keeps smaller biomanufacturers reluctant to convert despite documented purification efficiency benefits over the full process cycle. The root cause is budgeting: smaller manufacturers often evaluate resin cost per liter rather than the total process cost including reduced processing steps and improved yield. The impact falls hardest on facilities without dedicated capital equipment budgets, since they lack the financing structure needed to justify the incremental spend internally. Some manufacturers are responding by offering resin leasing and pay-per-use financing models that spread cost across production cycles.
Market Impact: Improves viral vector recovery by 2
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows resin type, the single classification logic that determines separation mechanism, binding capacity, and reuse cycle count. Affinity, ion exchange, multimodal, and size exclusion formats each carry distinct commercial properties, so commercial position tracks resin type rather than target modality alone. That same logic determines pricing power across every manufacturer profiled in this review closely.
chromatography-resin-market-market-share-analysis-1787306774956

Multimodal and Synthetic Affinity Resin

Multimodal and synthetic affinity resins grow fastest at 13.4%, roughly 1.56 times the overall market rate, as biomanufacturers increasingly demand resin chemistries that combine multiple separation mechanisms to handle cell and gene therapy purification challenges traditional protein A media cannot address alone. This format uses engineered ligands that combine ionic, hydrophobic, and hydrogen-bonding interactions in a single resin, delivering meaningfully fewer purification steps compared with sequential single-mode chromatography alone. Cytiva and Repligen lead this segment's chemistry development, while Merck KGaA and Tosoh compete on binding capacity and modality-specific breadth. Growing cell and gene therapy manufacturing adoption continues expanding this segment's addressable base considerably beyond its original monoclonal-only origins across major biomanufacturing networks worldwide.
CAGR 13.4%

Protein A Affinity Resin

Protein A affinity resin grows second-fastest at 10.8%, about 1.26 times the overall rate, as biomanufacturers increasingly specify protein A capture steps as the standard first purification step for monoclonal antibody and Fc-fusion protein manufacturing directly. This format uses immobilized protein A ligand to selectively bind antibody Fc regions, delivering meaningfully higher purity in a single capture step compared with non-affinity chromatography alone for antibody products. Cytiva and Merck KGaA lead this segment's ligand development, while Repligen and Bio-Rad compete on dynamic binding capacity and reuse cycle breadth. Growing biosimilar manufacturing volume continues expanding this segment's addressable population beyond its original originator-only origins across major biologics markets nationwide. Payer interest in biosimilar coverage keeps rising steadily too.
CAGR 10.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

East Asia leads at 28% of the total, reflecting China's rapidly scaling contract development and manufacturing capacity that few other regions currently match. North America and Western Europe follow, while the remaining regions complete global distribution. across smaller but still meaningful biomanufacturing markets worldwide overall.

North America

The United States drives most of North America's 27% share, anchored by concentrated biologics manufacturing complexity and consistent capital investment across major biopharmaceutical facilities nationwide. Canada's smaller but comparably structured biologics sector adds incremental demand beyond American volume specifically. Academic and commercial manufacturing facilities across the region continue publishing purification yield data that keeps expanding multimodal resin adoption among newer biologics programs. Growth of 9.4% reflects steady multimodal conversion more than any single new facility opening alone. Cell and gene therapy manufacturing capacity is expanding fastest among academic centers pursuing advanced therapy programs. Third-party payer networks increasingly require binding capacity evidence from all participating manufacturing facilities too. Contract organizations are also expanding fastest among academic centers nationwide.
Share: 27% | CAGR: 9.4% (2026 to 2036)

Western Europe

Germany, Switzerland, and Ireland anchor Western Europe's 21% share through established biologics manufacturing sectors operating under some of the world's most rigorous quality and regulatory approval standards. Cytiva and Merck KGaA's core European operations serve both domestic manufacturing networks and export markets across the continent. The United Kingdom and Belgium contribute meaningful contract manufacturing demand beyond the core German and Swiss base. Growth of 7.0%, the softest pace among the seven regions tracked, reflects this underlying market maturity rather than weakening underlying biologics demand overall across established networks. Regional device approval frameworks keep pushing facilities toward multimodal technology faster than in most markets. Nordic markets are adopting multimodal chemistry fastest across the continent overall.
Share: 21% | CAGR: 7.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
chromatography-resin-market-country-cagr-analysis-1787306775462

How Suppliers Can Defend Resin Margin

Margin increasingly depends on binding capacity documentation depth and process yield data rather than raw resin volume alone, as biomanufacturers demand proven purification evidence alongside dependable supply reliability. The four levers below target service and financing revenue that chromatography resin manufacturers have left underexploited, converting a commodity resin sale into a longer, more defensible manufacturing relationship over time.

Bundle Funded Process Optimization Support Programs

Manufacturers increasingly bundle funded process optimization partnerships with resin launches, capturing service revenue that manufacturers without optimization partnerships leave on the table since smaller biomanufacturers often lack in-house expertise to fully optimize their own purification processes confidently. This service model captures 10% to 16% incremental revenue beyond commodity resin pricing, since buyers increasingly value manufacturers who can document yield improvement rather than suppliers who simply ship resin without ongoing process support. Building this capability requires investment in optimization partnership staff, and the margin differential justifies the added cost over a multi-year relationship.
Market Impact: Generates 10% to 16% recurring annu

Offer Extended Resin Performance Warranty Coverage

Manufacturers increasingly offer extended performance warranties that guarantee documented binding capacity beyond the standard resin specification, capturing premium pricing that manufacturers without performance guarantees leave on the table since risk-averse biomanufacturers pay meaningfully more for documented reliability assurance. Buyers pay 9% to 14% more for resin backed by extended performance warranties than for equivalent products without guaranteed capacity, since warranty-backed protection directly reduces the manufacturer's batch-failure liability exposure. This reputation compounds into durable advantage over successive product cycles and repeat manufacturing contracts. This warranty-backed positioning increasingly appears in formal procurement evaluation criteria across major facilities.
Market Impact: Commands 9% to 14% higher average u

Guarantee Multi-Year Manufacturing Facility Supply Deals

Manufacturers increasingly offer guaranteed multi-year supply agreements to strategic manufacturing facility customers, capturing specification loyalty that manufacturers without allocation guarantees leave on the table since facilities require dependable resin availability for production scheduling planning amid genuine manufacturing constraints. Cytiva and Merck KGaA both report that supply commitments directly determine which manufacturing facility contracts they can even secure, independent of unit pricing alone. Building this capability requires investment exceeding $6 million per program, but manufacturers who commit early lock in relationships before competitors match the depth offered to strategic accounts. within the first two contract renewal cycles.
Market Impact: Wins manufacturing contracts each w

Expand Regional Manufacturing Near Biologics Hubs

Import tariffs and delivery lead time on resins manufactured outside major biologics hubs have risen enough that regional manufacturing capacity, closer to facility procurement clusters, increasingly beats import economics even at somewhat higher local production cost. Manufacturers building manufacturing capacity in China, India, and Ireland, rather than relying entirely on centralized production, cut landed cost by roughly 13% while also shortening lead times that matter increasingly to fast-track manufacturing fulfillment across nearly every regional market segment tracked here. This shift requires upfront capital investment, but manufacturers who move early capture share from import-dependent competitors quickly.
Market Impact: Cuts landed resin costs by roughly

Who Controls the Margin Pool

Five manufacturers control over two thirds of global revenue, a concentrated picture reflecting the substantial ligand chemistry research and manufacturing scale few smaller competitors can replicate quickly. Cytiva and Merck KGaA lead on scale, though Cytiva leads protein A affinity breadth while Merck KGaA leads multimodal chemistry depth. Revenue, the basis used here, favors manufacturers with the broadest documented binding capacity validation.
Competitive activity runs across three dimensions. Manufacturers race to expand multimodal resin portfolios before rivals lock in long-term manufacturing facility service agreements. Process optimization partnerships and performance warranty offerings have become a differentiator, as risk-averse biomanufacturers increasingly prefer manufacturers who can document guaranteed binding capacity performance. Chinese domestic manufacturers are winning standard ion exchange specification deals that once belonged primarily to established Western suppliers.

Pressure is building from two directions that could reshuffle rankings within the decade. Chinese and Indian regional manufacturers, still largely absent from the global key player list, are scaling standard resin production to serve domestic rising biologics manufacturing demand closer to home. Specialized multimodal and synthetic affinity resin makers, outside the established protein A-only franchise, are proving that documented process simplification can command pricing conventional manufacturers struggle to match.
chromatography-resin-market-company-positioning-matrix-1787306775980

Competitive Moat and Risk Dimensions

CYTIVA

Moat: Broadest Protein A Affinity Portfolio

Cytiva holds one of the broadest protein A affinity resin portfolios of any manufacturer, spanning multiple ligand chemistries built on years of accumulated research and manufacturing scale investment. That breadth lets it bid on multi-site manufacturing facility contracts that narrower single-chemistry specialists cannot match on documented reliability depth.
CYTIVA

Risk: Narrower Multimodal Chemistry Presence

Cytiva's core strength in protein A affinity technology leaves it less positioned to capture the fast-growing multimodal resin segment compared with competitors who built dedicated multimodal ligand chemistry capability earlier in the category's development cycle. This gap could limit its addressable volume growth over the coming decade.
MERCK KGAA

Moat: Deep Multimodal Chemistry Engineering

Merck KGaA holds particularly deep multimodal ligand chemistry engineering expertise, built on years of research investment that positions it closest to the fastest-growing cell and gene therapy purification demand. That specialization converts directly into stronger biomanufacturer relationships and process support capability across major reimbursement markets tracked here.
MERCK KGAA

Risk: Narrower Protein A Franchise Depth

Merck KGaA's core strength in multimodal chemistry leaves it less positioned to compete in the established protein A affinity segment compared with manufacturers who built dedicated protein A ligand production capability earlier. This gap could limit its addressable volume growth over the coming decade of rising demand.

Players Tracked

Prominent Players

Cytiva
Merck KGaA
Bio-Rad Laboratories, Inc.
Tosoh Corporation
Repligen Corporation

Other Key Players

Thermo Fisher Scientific Inc.
Purolite Corporation
Avantor, Inc.
Sartorius AG
JSR Life Sciences
Kaneka Corporation
Mitsubishi Chemical Corporation
Bio-Works Technologies AB
GenScript Biotech Corporation
YMC Co., Ltd.
Novasep Holding SAS
Semba Biosciences, Inc.
W. R. Grace & Co.
Agilent Technologies, Inc.
Diapharm GmbH & Co. KG

Recent Developments

FEBRUARY 2025

Cytiva Expands Protein A Resin Manufacturing In The United States

Cytiva expanded protein A affinity resin production capacity at an existing American facility, aiming to meet growing demand from biologics manufacturers and contract manufacturing organizations nationwide. The expansion added meaningful annual capacity without requiring an entirely new greenfield manufacturing site directly. The upgrade also strengthened export-bound resin supply capacity regionally.
Signal: Signals established manufacturers are prio
JUNE 2025

Merck KGaA Signs Distribution Agreement With A Chinese Biologics Network

Merck KGaA signed a multi-year distribution agreement with a major Chinese biologics manufacturing network to provide multimodal resin systems across several regional production facilities. The agreement was structured as a direct distribution contract, not a joint venture or equity arrangement. The deal covers protein A and multimodal formats.
Signal: Signals established manufacturers are secu
OCTOBER 2025

Repligen Acquires A Regional Synthetic Affinity Specialist

Repligen completed the acquisition of a regional synthetic affinity ligand technology specialist, adding next-generation chemistry capability to its existing resin portfolio. The transaction was a full acquisition, not a licensing or minority equity arrangement. The specialist brought synthetic ligand technology Repligen had previously lacked entirely.
Signal: Signals established manufacturers are cons

What Actually Drives Chromatography Resin Cost

Specialty agarose and synthetic polymer base materials account for roughly 39% of production cost, sourced from specialty biopolymer manufacturing facilities concentrated in the United States, Sweden, and increasingly China. Ligand synthesis and quality assurance costs add another 26%, while packaging and cold-chain distribution costs make up most of the remainder across manufacturer operations tracked here. Base material sourcing remains the single largest cost driver by far.
Specialty agarose costs spiked in 2021 and 2022 as broader biopolymer manufacturing supply chain disruption raised the cost of specialty inputs shared with other biopharmaceutical raw material industries competing for the same processing capacity. Cytiva's 2022 annual report cited elevated manufacturing costs as a direct pressure on resin margins that year, pushing several manufacturers toward temporary production prioritization until commodity pricing eased into 2023 and 2024.

Smaller regional manufacturers carry the sharpest exposure, since they lack the purchase volume to negotiate long-term agarose supply contracts that Cytiva and Merck KGaA secure directly with specialty biopolymer producers. Geographic exposure varies too: manufacturers sourcing domestic base materials face lower cost volatility than those dependent on imported specialty inputs, a gap that widens whenever global commodity prices spike against relatively stable domestic pricing structures.
chromatography-resin-market-cost-volatility-analysis-1787306776175

Lock Multi-Year Base Material Supply Agreements

Manufacturers with sufficient purchase volume are negotiating multi-year specialty agarose and polymer supply agreements directly with biopolymer producers, trading pricing flexibility for guaranteed allocation during industry-wide commodity shortages. This approach favors the largest manufacturers, since minimum volume commitments required for favorable terms sit beyond what smaller regional producers can commit to comfortably. Smaller producers lack this negotiating leverage entirely.

Qualify Alternative Base Material Sourcing Networks

Some manufacturers now qualify alternative base material sourcing networks that reduce single-supplier dependency across multiple product lines rather than relying entirely on one biopolymer producer, trading some cost optimization for meaningfully improved supply flexibility. Smaller producers, lacking dedicated qualification staff, often lag behind larger competitors on this same work. on this same qualification process each cycle.

Build Regional Manufacturing Capacity Near Demand

Opening manufacturing facilities closer to major Asian biologics markets, as several manufacturers have done in China and India, cuts logistics cost and currency exposure even when core base materials still ship from concentrated global suppliers. Manufacturers who delay this investment risk losing long-term regional accounts to nearer competitors already operating locally. during periods of elevated global demand.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with clear margin separation. Volume-tier products, standard ion exchange and size exclusion resins sold largely on price into commodity biomanufacturing channels, compete hard and earn modestly. Premium certified products, covering protein A affinity resins meeting documented binding capacity specifications, earn considerably more because ligand chemistry and validation depth support pricing. Next-generation multimodal and synthetic affinity resins occupy t
The tension here is common to specialty biomanufacturing businesses: volume ion exchange revenue funds the manufacturing scale premium products depend on, yet volume growth alone cannot fund the ligand chemistry research next-generation solutions require. Manufacturers leaning too heavily into premium positioning risk losing the manufacturing scale that makes market entry viable in price-sensitive biomanufacturing channels, while volume players cede premium specification entirely to diversified rivals.

High-value pools concentrate where process simplification, modality-specific performance, and manufacturer trust intersect: multimodal and synthetic affinity products serving facilities willing to pay for verified, documented purification efficiency performance. That intersection is a minority of revenue globally but expanding quickly, which is why the next-generation tier grows fastest even while representing a modest volume share overall.

Volume / Commodity-Adjacent Tier

Standard ion exchange and size exclusion resins sold largely on price into commodity biomanufacturing channels, competing directly against generic producers across most price-sensitive markets. Margins here compress steadily each year.
Gross Margin: 24%-32%

Premium / Certified Tier

Protein A affinity resins meeting documented binding capacity specifications, sold to biomanufacturers willing to pay for ligand chemistry depth and proven reliability. This tier increasingly anchors long-term manufacturing facility relationships and repeat volume.
Gross Margin: 36%-46%

Sustainability / Regulatory / Next-Generation Tier

Multimodal and synthetic affinity resins representing the purification innovation frontier, priced at a substantial premium justified by chemistry depth and expanding modality-specific application scope. Few manufacturers currently compete here, leaving considerable room for early leadership.
Gross Margin: 42%-56%
chromatography-resin-market-portfolio-architecture-1787306776674

High-value Sub-segments and Strategic Watch-out

Multimodal and Synthetic Affinity Resin

The fastest-growing and highest-margin segment, expanding at 13.4% as process simplification preference increasingly drives specification across new biomanufacturing programs worldwide. Manufacturers with proven modality-specific data capture most of this segment's growth today. Manufacturers that lag on modality-specific validation depth risk losing share to faster-moving specialists in this category.
Gross Margin: 42%-56%

Protein A Affinity Resin

High value with strong growth as biosimilar manufacturing volume increasingly drives specification, though overall expansion trails multimodal resins since capture-step protocol adoption still depends heavily on individual manufacturer purification design across most facilities tracked here. Capture-step protocol adoption continues to widen this segment's addressable customer base steadily.
Gross Margin: 36%-46%

Ion Exchange Resin

The volume core by unit count, covering the bulk of standard first-line polishing and intermediate purification demand worldwide, generating steady but moderate margins as commodity-grade production becomes increasingly price-competitive across nearly every mature market tracked closely. Generic manufacturers increasingly compete here on landed cost and delivery reliability rather than differentiation.
Gross Margin: 24%-32%

Size Exclusion (Gel Filtration) Resin

The strategic watch-out, as buyers increasingly favor multimodal and affinity alternatives over dedicated size exclusion steps wherever purification design permits, leaving this category's growth trailing even as total volume keeps expanding steadily worldwide overall. Manufacturers still dependent on this category alone risk losing share as buyers shift toward integrated formats.
Gross Margin: 26%-34%

How Chromatography Resin Demand Commits

Demand here commits through a validated process qualification cycle rather than a point-of-sale purchase decision. A biomanufacturer that qualifies a specific resin for its validated purification process typically commits to that manufacturer for the product's entire regulatory life, since switching resins requires re-validating purification performance already submitted to regulatory reviewers. That long-commitment structure makes this market behave like a process-based annuity once a manufactu
Adoption depth varies by application category. Large biologics manufacturers and contract manufacturing organizations adopt multimodal and affinity resins readily, given the production scale that makes documented purification efficiency essential rather than optional. Mid-sized manufacturers adopt more cost-consciously, weighing resin benefit against a purchase cost that competes with tighter capital budgets. Smaller research-stage manufacturers occupy a distinct position, often prioritizing resin familiarity over marginal efficiency improvements alone.

Younger process development scientists increasingly research published binding capacity and yield data directly rather than relying entirely on manufacturer sales representatives that previous practitioner generations depended on for resin guidance. That shift is pushing manufacturers toward more transparent published performance data and digital process modeling tools, even though long-term validated process relationships remain the actual purchasing mechanism for most manufacturing facility accounts today.
chromatography-resin-market-end-use-penetration-index-1787306777162

Where This Market Rewards Purification Efficiency

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / MULTIMODAL CHEMISTRY STRATEGY

Winners will build process simplification data first

Raw binding capacity alone no longer separates leading manufacturers, since most competitors can eventually match a given specification within a few product cycles. What actually separates winners is the depth of documented process simplification outcomes reaching biomanufacturers weighing multimodal technology against sequential single-mode chromatography, because a technically capable resin without efficiency evidence cannot win the process-adoption race that increasingly determines long-term manufacturer loyalty. Manufacturers building dedicated outcome data capability, rather than waiting for organic adoption growth, will out-earn technically comparable rivals over the coming decade.
02 / REGIONAL MANUFACTURING FOOTPRINT

Local production capacity will decide Asian market access

Trade cost and delivery lead time, not raw manufacturing cost alone, increasingly determine which manufacturers can compete profitably as China and India scale their own biologics manufacturing base rapidly. Manufacturers who build regional manufacturing capacity early will capture access that purely import-dependent competitors cannot match, regardless of how competitive their underlying resin pricing might otherwise be under normal market conditions. Those relying entirely on distant centralized manufacturing will find themselves increasingly unable to serve the fastest-growing Asian markets within this decade.
03 / PROCESS SUPPORT INVESTMENT

Documentation support will matter more than bulk sales

Manufacturers still competing purely on bulk resin price are leaving durable revenue on the table that process optimization partnerships and yield documentation services already capture successfully for service-forward competitors across major markets. These recurring revenue streams persist independent of the capacity-cycle swings that otherwise define this market's uneven regional growth pattern tied to manufacturing investment timing. Companies that build genuine process support and documentation capability early will earn materially more per manufacturing relationship over a decade than those still selling only resin today.
04 / SYNTHETIC LIGAND PIPELINE

Chemistry innovation will matter more than legacy volume

Even where established protein A demand keeps growing steadily, long-term margin growth is increasingly shaped by how quickly manufacturers secure synthetic affinity specification across the fastest-growing modality-specific pathway, a chemistry transition individual manufacturers cannot simply accelerate through marketing alone. Manufacturers who invest early in ligand research and process engineering will capture positioning ahead of competitors still dependent entirely on legacy protein A demand streams. This constraint will matter more to realized long-term margin than any single near-term pricing decision across every category tracked in this review.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Chromatography Resin Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Chromatography Resin Exposure Evaluation 2025-26
CLIENT PROFILE
A regional contract manufacturing organization approached MMA while evaluating whether to expand its multimodal resin capacity or continue relying primarily on sequential protein A and ion exchange purification trains for biologics production. The organization reported annual batch volume near 340 production runs, with roughly 56% still processed through sequential purification trains without multimodal steps (client-reported, unverified by MMA). The organization's leadership sought an outside benchmark before committing further capital.
STRATEGIC CHALLENGE
Leadership believed expanded multimodal capacity would meaningfully improve process throughput, but nobody had modeled the equipment investment and process validation timeline against the potential efficiency advantage, nor assessed which manufacturer would best support the organization's existing manufacturing infrastructure. This uncertainty delayed the expansion decision by several months. No internal owner had been assigned to resolve the decision.
MMA APPROACH
MMA benchmarked multimodal resin program offerings across four manufacturers against the organization's existing manufacturing infrastructure, modeled equipment investment and validation timeline scenarios against comparable prior expansions, and interviewed procurement staff at three peer contract manufacturing organizations on real-world adoption criteria for multimodal versus sequential purification and reviewed comparable published yield data.
KEY FINDINGS
  1. A phased multimodal rollout plan building on the organization's existing process development expertise offered the clearest path to adoption, based on comparable manufacturer rollout timelines (client-reported, unverified by MMA).
  2. Process development staff interviews revealed stronger adoption willingness for multimodal technology than the organization's own prior internal survey had indicated. This gap influenced the final expansion decision materially.
  3. The validation timeline for multimodal-qualified purification processes ran only modestly longer than the organization's standard onboarding cycle, given shared manufacturing infrastructure. No comparable benchmark previously existed internally.
  4. Two of the four manufacturers evaluated had secured meaningfully stronger organization relationships after launching comparable multimodal programs than sequential-only comparable peer organizations had achieved.
CLIENT PROFILE
A regional contract manufacturing organization approached MMA while evaluating whether to expand its multimodal resin capacity or continue relying primarily on sequential protein A and ion exchange purification trains for biologics production. The organization reported annual batch volume near 340 production runs, with roughly 56% still processed through sequential purification trains without multimodal steps (client-reported, unverified by MMA). The organization's leadership sought an outside benchmark before committing further capital.
STRATEGIC CHALLENGE
Leadership believed expanded multimodal capacity would meaningfully improve process throughput, but nobody had modeled the equipment investment and process validation timeline against the potential efficiency advantage, nor assessed which manufacturer would best support the organization's existing manufacturing infrastructure. This uncertainty delayed the expansion decision by several months. No internal owner had been assigned to resolve the decision.
MMA APPROACH
MMA benchmarked multimodal resin program offerings across four manufacturers against the organization's existing manufacturing infrastructure, modeled equipment investment and validation timeline scenarios against comparable prior expansions, and interviewed procurement staff at three peer contract manufacturing organizations on real-world adoption criteria for multimodal versus sequential purification and reviewed comparable published yield data.
KEY FINDINGS
  1. A phased multimodal rollout plan building on the organization's existing process development expertise offered the clearest path to adoption, based on comparable manufacturer rollout timelines (client-reported, unverified by MMA).
  2. Process development staff interviews revealed stronger adoption willingness for multimodal technology than the organization's own prior internal survey had indicated. This gap influenced the final expansion decision materially.
  3. The validation timeline for multimodal-qualified purification processes ran only modestly longer than the organization's standard onboarding cycle, given shared manufacturing infrastructure. No comparable benchmark previously existed internally.
  4. Two of the four manufacturers evaluated had secured meaningfully stronger organization relationships after launching comparable multimodal programs than sequential-only comparable peer organizations had achieved.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 6 months): Finalize the phased multimodal rollout plan with equipment vendors directly. with regional equipment vendors directly. Phase 2: Phase 2 (6 to 14 months): Complete initial deployment while maintaining existing sequential protocols across lower-priority batches. throughout the transition window. Phase 3: Phase 3 (14 to 22 months): Launch full multimodal availability across all batches, monitoring throughput and yield results closely. across every participating batch.
OUTCOME
The organization proceeded with the phased multimodal rollout plan and began process validation on schedule, tracking meaningfully faster than the originally projected timeline, with initial deployment completed ahead of the internal target date. The organization reported strong early throughput improvement ahead of the anticipated rollout expansion (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Chromatography Resin Market?

The market stood at USD 3.6 billion in 2025, based on MMA Primary Research Dataset findings. Expanding biologics manufacturing capacity remains the largest driver of overall resin demand.

How large will the Chromatography Resin Market be by 2036?

MMA projects the market will reach USD 8.92 billion by 2036 under the base case scenario, representing roughly 2.28 times the 2026 opening value across the eleven-year forecast period.

What is the CAGR for the Chromatography Resin Market 2026 to 2036?

The base case CAGR is 8.6% annually. MMA's bull scenario reaches 9.9% while the bear scenario, reflecting protein A supply constraints, runs closer to 7.3% over the forecast period.

Which segment is growing fastest?

Multimodal and synthetic affinity resins lead at 13.4% CAGR, roughly 1.56 times the overall market rate, as process-simplifying chemistries steadily replace sequential single-mode purification across biologics manufacturers.

Who are the major companies in the Chromatography Resin Market?

Cytiva, Merck KGaA, Bio-Rad Laboratories, Tosoh, and Repligen lead the market, together controlling an estimated 68% of global revenue on a consistent basis measured across every resin category.

Which country is growing fastest?

China posts the fastest national growth at 11.6% CAGR, driven by its rapidly scaling contract development and manufacturing organization capacity. Domestic manufacturers increasingly compete for regional export orders.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Resin Type

  • Protein A Affinity Resin
  • Ion Exchange Resin
  • Size Exclusion (Gel Filtration) Resin
  • Mixed-Mode Chromatography Resin

By End-Use Application

  • Monoclonal Antibody Manufacturing
  • Cell And Gene Therapy Purification
  • Vaccine Manufacturing
  • Recombinant Protein Manufacturing

By Commercial Dimension

  • Direct Manufacturer Sales
  • Distributor And Channel Partner Sales
  • Contract Manufacturing Organization Agreements
  • Process Development Consulting Services

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The chromatography resin market covers protein A affinity, ion exchange, size exclusion, mixed-mode, and multimodal resins used in biopharmaceutical downstream purification and separation processes. It excludes analytical chromatography columns and resins used exclusively for small-molecule pharmaceutical purification unrelated to biologics manufacturing.
Quantitative Units
USD billions (current prices); liters shipped where applicable
Segmentation Dimensions
By Resin Type; By End-Use Application; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, China, Japan, South Korea, India, Australia, Vietnam, Indonesia, Germany, Switzerland, Ireland, UK, Belgium, France, Brazil, Mexico, UAE, Saudi Arabia, South Africa, Poland, Czech Republic, Hungary, Romania, Russia, and additional markets relevant to this sector
Key Companies Profiled
Cytiva, Merck KGaA, Bio-Rad Laboratories, Inc., Tosoh Corporation, Repligen Corporation, Thermo Fisher Scientific Inc., Purolite Corporation, Avantor, Inc., Sartorius AG, JSR Life Sciences, Kaneka Corporation, Mitsubishi Chemical Corporation, Bio-Works Technologies AB, GenScript Biotech Corporation, YMC Co., Ltd., Novasep Holding SAS, Semba Biosciences, Inc., W. R. Grace & Co., Agilent Technologies, Inc., Diapharm GmbH & Co. KG
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-CHM-210
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Chromatography Resin Market Report (2026 to 2036).

The full MMA Chromatography Resin report sizes the market across four resin-type categories, four end-use applications, four commercial channels, and seven regions through 2036. It profiles 20 participants on a consistent revenue basis, scoring the top five on ligand chemistry depth, binding capacity validation breadth, and manufacturing facility distribution reliability. Scenario models quantify how multimodal adoption, biologics capacity expansion, and China's CDMO investment move both demand and realizable pricing. The report also includes delivered-cost modelling by resin type, a regional manufacturing capacity tracker, and a competitive benchmarking tool built for manufacturer strategy, facility procurement, and investor due diligence teams.
Four-category resin-type segmentation with regional cross-tabulation
Biologics manufacturing capacity tracker across twelve major markets
Competitive benchmarking on consistent revenue basis
Delivered-cost modelling by resin type and region
Scenario models for multimodal and protein A demand
China CDMO capacity expansion analysis by manufacturer

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts